Cited 0 times in Scipus Cited Count

Changes in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy

DC Field Value Language
dc.contributor.authorChung, YR-
dc.contributor.authorLee, SJ-
dc.contributor.authorSong, JH-
dc.date.accessioned2023-02-27T07:13:00Z-
dc.date.available2023-02-27T07:13:00Z-
dc.date.issued2022-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/24928-
dc.description.abstractWe evaluated the effect of intravitreal bevacizumab injection (IVB) on choroidal thickness, and studied its association with the therapeutic response in chronic central serous chorioretinopathy (CSC). The clinical features of 78 eyes with chronic CSC treated with IVB from October 2014 to June 2020 were retrospectively evaluated. Visual acuity (VA), central retinal thickness (CRT), and sub-foveal choroidal thickness (SFCT) were analyzed at baseline, 1 month following initial IVB, and the last follow-up examination. Cases showing complete recovery (resolved eyes; n = 60) were compared with those with persistent subretinal fluid (refractory eyes; n = 18). The relationship between the potential risk factors and subretinal fluid resolution was examined using logistic regression. SFCT was significantly decreased along with the CRT following IVB at the resolved state. SFCT reduction following 1 month of IVB was notably greater in the resolved eyes. The association of refractory eyes with hypertension (p = 0.003) and a thinner baseline SFCT (p = 0.024) was significant. In most of the patients with chronic CSC, VA and CRT remarkably improved following treatment with IVB. Early changes in the SFCT following IVB were associated with the therapeutic response. Patients with hypertension and a thinner baseline SFCT could be unresponsive to IVB.-
dc.language.isoen-
dc.titleChanges in the Choroidal Thickness following Intravitreal Bevacizumab Injection in Chronic Central Serous Chorioretinopathy-
dc.typeArticle-
dc.identifier.pmid35743446-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224583-
dc.subject.keywordbevacizumab-
dc.subject.keywordcentral serous chorioretinopathy-
dc.subject.keywordchoroidal thickness-
dc.contributor.affiliatedAuthorChung, YR-
dc.contributor.affiliatedAuthorSong, JH-
dc.type.localJournal Papers-
dc.identifier.doi10.3390/jcm11123375-
dc.citation.titleJournal of clinical medicine-
dc.citation.volume11-
dc.citation.number12-
dc.citation.date2022-
dc.citation.startPage3375-
dc.citation.endPage3375-
dc.identifier.bibliographicCitationJournal of clinical medicine, 11(12). : 3375-3375, 2022-
dc.identifier.eissn2077-0383-
dc.relation.journalidJ020770383-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Ophthalmology
Files in This Item:
35743446.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse